FDA Approves Possis AngioJet Ultra Thrombectomy System
Possis Medical, a developer, manufacturer and marketer of medical devices for the cardiovascular and vascular treatment markets, today announced that it has received marketing approval from the FDA for its new AngioJet Ultra Thrombectomy System. The AngioJet was introduced in 1997 and has been used to treat 300,000 patients worldwide said Robert G. Dutcher, the company’s chairman, president and CEO. The benefits claimed by Possis for the new version of its product are:
- A simpler setup process than the 20-step process required to set up the original AngioJet drive unit.
- More flexibility to use a broad range of catheters.
- A lighter, more compact design make it easier to move the device around the hospital.
According to the company, 95 percent of top coronary labs have Possis’ AngioJet System and more than 1,700 systems installed across the U.S. (what it takes to be a “top” lab wasn’t defined in the press release.)
December 18, 2006 Related topics: Product Approval & Certification, Cardiology